The current ELN guidelines propose a cutoff of 0.1% of CD45+ cells for AML MRD, supported by published data while acknowledging that lower levels of MRD, ranging from 0.01% to 0.1% CD45+ cells, may still hold clinical significance [5,14,24]. This evidence concerns the gene PTPRC and acute myeloid leukemia.